GAD2 and type 1 diabetes mellitus: This study should be considered in the landscape of a series of research projects aiming to explore the antigen-specific immunotherapy (based on the subcutaneous administration of glutamic acid decarboxylase 65, GAD65) as a strategy to preserve the β-cell function in patients with T1DM [71,72,73,74].